About: Ethical issues related to the hydroxychloroquine treatment prescription for Covid-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ethical issues related to the hydroxychloroquine treatment prescription for Covid-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Ethical issues related to the hydroxychloroquine treatment prescription for Covid-19
Creator	Adarmouch, Latifa Rhazi, Karima
Source	Elsevier; Medline; PMC; WHO
abstract	Abstract The 2019-20 coronavirus pandemic (COVID-19), has led to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, no drugs have demonstrated safety and efficacy in randomized controlled trials for patients with COVID-19. Although the association between Hydroxychloroquine and Azithromycin efficacy lack of solid evidence-base, several governments have adopted it for all virology confirmed Covid-19 cases even for those who are asymptomatic. In the following, we aim to discuss some of the ethical issues associated with the use of this treatment association. We mainly tried to discuss the following controversial questions: Is it ethical not to treat a patient while a treatment exists and is used for other indications than Covid-19 for which it’s not proven yet? If yes, is a randomized controlled trial to prove the hydroxychloroquine for the Covid-19 treatment, necessary, in the context of covid-19 pandemic? If No, is it the government’s right to decide the hydroxychloroquine treatment for all covid-19 patients? and what should be the physicians’ attitudes? Finally, what are the government, physicians, and patient’s rights and responsibilities? The paper conclude that, since health authorities in some countries recommended this off-label use treatment, physicians are challenged by the requirement of veracity while providing care to their patients and the implications of such a requirement; they are facing the challenge of balancing this guideline and their own conviction. Furthermore, the fundamental principles of beneficence and non-maleficence, and respect for persons should underlie any reflection process to address this dilemma. In addition, in a pandemic context, the limits between the government’s, practitioner’s and patient’s rights and obligations are not clear which could significantly endanger the universal ethical principles in clinical practice. It could also undermine any attempt to develop serious clinical trials to prove the considered off-label drug.
has issue date	2020-06-17(xsd:dateTime)
bibo:doi	10.1016/j.jemep.2020.100547
bibo:pmid	32835062
has license	els-covid
sha1sum (hex)	3de5c608083200ee3ee8bf4131bb6d618a85a5d9
schema:url	https://doi.org/10.1016/j.jemep.2020.100547
resource representing a document's title	Ethical issues related to the hydroxychloroquine treatment prescription for Covid-19
has PubMed Central identifier	PMC7298480
has PubMed identifier	32835062
schema:publication	Ethics Med Public Health
resource representing a document's body	covid:3de5c608083200ee3ee8bf4131bb6d618a85a5d9#body_text
is schema:about of	named entity 'Covid' named entity 'Covid' named entity 'hydroxychloroquine' named entity 'Covid' named entity 'à la' named entity 'viruses' named entity 'shared decision-making' named entity 'MEURI' named entity 'Hydroxychloroquine' named entity 'symptomatic treatment' named entity 'critically ill patients' named entity 'public health' named entity 'malaria treatment' named entity 'MEURI' named entity 'Covid-19' named entity 'China' named entity 'Covid-19 pandemic' named entity 'COVID-19' named entity 'off-label' named entity 'Covid-19' named entity 'hydroxychloroquine' named entity 'Covid-19' named entity 'morbidity' named entity 'le droit' named entity 'probability' named entity 'Democratic Republic of Congo' named entity 'social vulnerability' named entity 'off-label' named entity 'off-label' named entity 'MEURI' named entity 'developed countries' named entity 'Covid-19' named entity 'Randomized Clinical' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'hydroxychloroquine' named entity 'off-label' named entity 'off-label' named entity 'Ebola' named entity 'Covid 19' named entity 'off-label' named entity 'hydroxychloroquine' named entity 'off-label' named entity 'CFR' named entity 'off-label' named entity 'COVID-19' named entity 'developing countries' named entity 'randomized controlled clinical trials' named entity 'hydroxychloroquine' named entity 'Ebola' named entity 'clinical practice' named entity 'off-label' named entity 'smallpox vaccination' named entity 'hydroxychloroquine' named entity 'quality of life' named entity 'Hydroxychloroquine' named entity 'randomized controlled trial' named entity 'coronavirus 2' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'pharmaceutical companies' named entity 'public health' named entity 'randomized controlled trials' named entity 'off-label' named entity 'off-label' named entity 'hydroxychloroquine' named entity 'case fatality rate' named entity '2, 3' named entity 'Ebola' named entity 'Covid-19' named entity 'Hydroxychloroquine' named entity 'Covid-19' named entity 'clinical trials' named entity 'hydroxychloroquine' named entity 'covid-19' named entity 'Off-label prescription' named entity 'Morocco' named entity 'systematic review' named entity 'treat patients' named entity 'medical ethics' named entity 'Covid-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software